Oct 9 2013
Global Bioenergies is developing a process to convert renewable resources into hydrocarbons through fermentation collecting volatile olefins purified through an extraction process. Initially focus was in efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the yield of its process and prepares the phase dedicated to industrial pilot testing. The company recently replicated this to propylene and butadiene and is also looking to continue with other members of the gaseous olefins family, key molecules at the heart of petrochemical industry. The company is now concentrating its efforts on the industrialization of the isobutene process which consists in increasing yields and scaling up of the processNow and industrial scale pilot is under construction.
The company’s strategy is to develop the industrial case for isobutene, then license out the technology to industrial partners, which have the resources to build a production facility. To fund R&D on several light olefins simultaneously, it has secured grants from government agencies (eg OSEO in France) and industrial partnerships, the best example being the butadiene programme, in partnership with Synthos
Global Bioenergies is listed on NYSE Alternext Paris (FR0011052257 – ALGBE)
Founded in 2008
Global Bioenergies was founded in October 2008 by Marc Delcourt and Philippe Marlière. In February 2009, the company raised €3.2m ($4.6m) from Seventure Partners, the VC (Venture Capital) subsidiary of BPCE, one of France’s main banks.
In 2009, a proof of concept was obtained for the process leading to the bio-production of isobutene. A lab-scale prototype was built in 2010. Two preliminary agreements have been signed on the isobutene process, one with an American major and one with a German car manufacturer.
In July 2011, Global Bioenergies has performed its IPO to raise the capital necessary to the development of its isobutene process. €6.6m have thus been raised on the NYSE Alternext market in Paris.
In July 2011, the Company has announced the signature of a partnership with Synthos to replicate to butadiene the success originally obtained on isobutene, another member of the light olefins family. A milestone in this partnership has been reached in December 2012 which has resulted in the payment of €2.7m by Synthos to Global Bioenergies. The butadiene process is now in its development phase.
In June 2013, the Company announced the beginning of the industrial pilot phase of its isobutene process, in collaboration with Arkema and supported by a €5.2m financing to be received from the French State (“Investissements d’Avenir” program).
Main share holder is the venture capital company Seventure partners holding 39.7%, founders Marc Decourt and Philippe Marliere has shares for the same level, the ethanol producer Cristal Union holds 4,9 percent, Synthos 3,3% and rest is with the public 13,4%. (Feb 2013)
Tomas Buhl is head of business development